Lengyel Lab

New in @Nature: Drs. @ErnstLengyel, @JannaHeide, @OvCa_UChicago & team discovered a first-of-its-kind NNMT inhibitor that reprograms cancer-associated fibroblasts & restores immune response in ovarian cancer, marking a major step toward better therapies. nature.com/articles/s4158…

🔥 Hot off the press: In a new @Nature study, @ErnstLengyel and team show that blocking NNMT in tumor-supporting cells restores immune response & stops ovarian cancer growth, offering a new strategy for hard to treat cancers. @OvCa_UChicago @uchicago_obgyn ow.ly/zzfZ50Wu3UW

Online Now: Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression dlvr.it/TLbW6y

New from the Lengyel/Kenny Lab: our study in @Cancer_Cell with @labs_mann charts how borderline ovarian tumors evolve into low-grade serous ovarian cancer, using spatial proteo-transcriptomics to uncover molecular drivers & potential therapeutic targets. sciencedirect.com/science/articl…

Proud to share our latest work now in @Cancer_Cell. In collaboration with @MPI_Biochem, we map the progression from borderline ovarian tumors to low-grade serous ovarian cancer & propose a promising new therapeutic strategy. sciencedirect.com/science/articl… #LGSC #SBT

An interdisciplinary study @labs_mann & @uchicago_obgyn uncovers how benign borderline ovarian tumors develop into invasive low-grade serous carcinoma, opening a new avenue for targeted therapy. ❕Publication: cell.com/cancer-cell/fu… ❕Press Release: biochem.mpg.de/when-tumors-tu…

Our paper on ovarian cancer #LGSC is out in @Cancer_Cell. Using deep visual proteomics #DVP and spatial transcriptomics, we mapped how non-invasive tumors become deadly ovarian disease, and found a promising new treatment combination. cell.com/cancer-cell/fu…

We're excited to share that our latest work is featured on the cover of @CCR_AACR. This multi-institutional study offers the 1st systematic proteogenomic analysis of synchronous endometrial and ovarian cancers (SEOC). bit.ly/4kVgq9L @ErnstLengyel @Mad_PhD @labs_mann

We received the cover for our recent publication in @CCR_AACR. This multi-institutional study offers the first systematic proteogenomic analysis of synchronous endometrial and ovarian cancers (SEOC). Read: bit.ly/4kVgq9L @OvCa_UChicago @Mad_PhD @labs_mann

New publication led by Dr. Hilary Kenny, now in @MCT_AACR: Dual inhibition of Bcl-2/xL (navitoclax) and survivin (YM155), combined with carboplatin, reduces ALDH^hi cell populations and tumor burden in HGSOC models. Read: aacrjournals.org/mct/article-ab…

Hello all, Join us for an insightful lecture by Professor Matthias Mann Ph.D. Proteomics Pioneer Lecture- 7/31, 9am

Congrats to @Abir_Mukherjee_ @ErnstLengyel & team at @OvCa_UChicago for uncovering mechanism of metabolic reprogramming in ovarian cancer metastasis!

Happy to announce that our recent adipocyte-cancer cell interaction paper is online. We describe a metabolic adaptation of metastatic ovarian tumors to colonize the adipose tissue.

Great study coming from @uchicago_obgyn @OvCa_UChicago - demonstrating good reproducibility of adnexal mass scoring systems to predict malignancy in a cohort of over 500 patients. Great work @Roni_YoeliBik @ErnstLengyel

Dr. Yoeli-Bik from our lab showed that the The Simple Rules, ADNEX, and O-RADS ultrasound-based models can accurately differentiate benign from malignant adnexal lesions. ja.ma/44MHlg5 @OvCa_UChicago @uchicago_obgyn @Roni_YoeliBik @Mad_PhD @Jacquesdeparis1

The Simple Rules, ADNEX, and O-RADS ultrasound-based models can accurately differentiate benign from malignant adnexal lesions. ja.ma/44MHlg5 @OvCa_UChicago @uchicago_obgyn @Roni_YoeliBik @GeneticWhisper @Mad_PhD @Jacquesdeparis1 @ErnstLengyel

Looking forward to the release of this episode, and the debut of my first podcast. Thanks @NCI_Bogler for this wonderful opportunity. @theNCI

Great visit by @shouval today @OvCa_UChicago! So nice to meet you and share the excitement for CAFs and their central role in the TME.